valproic acid has been researched along with Cancer of Liver in 34 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib resistance is a classic problem related to the treatment of advanced hepatocellular carcinoma (HCC)." | 7.96 | Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. ( Liang, Q; Liu, J; Shen, X; Sun, G; Yang, X; Yu, Y, 2020) |
| "Valproic acid (VPA), a well-known histone deacetylase (HDAC) inhibitor, is used as an anti-cancer drug for various cancers, but the synergistic anti-cancer effect of VPA and doxorubicin (DOX) combination treatment and its potential underlying mechanism in hepatocellular carcinoma (HCC) remain to be elucidated." | 7.85 | Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells. ( Cho, SG; Choi, HY; Dayem, AA; Kim, K; Saha, SK; Yang, GM; Yin, Y, 2017) |
| " Here, we compared combined effect of valproic acid (VPA), a class I and II HDAC inhibitor and antiepileptic drug with proton and photon irradiation in hepatocellular carcinoma (HCC) cells in vitro and in vivo." | 7.85 | Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation. ( Choi, C; Kim, SY; Lee, GH; Park, HC; Shin, SW; Son, A; Yu, JI, 2017) |
| "Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases." | 7.80 | Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. ( Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S, 2014) |
| " He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery." | 7.73 | Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. ( Iizuka, H; Katsuda, S; Okamoto, K; Sato, K; Ueda, Y; Ueno, K, 2005) |
| "For this purpose, PLC/PRF5 liver cancer cells were cultured, and after the overlapping of the cells reached about 80%, the cells were collected with trypsin and after washing, they were cultured on a plate with a concentration of 3 x 105." | 5.72 | Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line. ( Jiang, L; Liu, Y; Lu, Y; Zhang, K, 2022) |
| "Sorafenib resistance is a classic problem related to the treatment of advanced hepatocellular carcinoma (HCC)." | 3.96 | Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. ( Liang, Q; Liu, J; Shen, X; Sun, G; Yang, X; Yu, Y, 2020) |
| "and combined, on hepatocellular carcinoma Hep G2 cell line." | 3.91 | Effect of DNA Methyltransferase in Comparison to and\ in Combination with Histone Deacetylase Inhibitors on\ Hepatocellular Carcinoma HepG2 Cell Line ( Kavoosi, F; Sanaei, M, 2019) |
| "Valproic acid (VPA), a well-known histone deacetylase (HDAC) inhibitor, is used as an anti-cancer drug for various cancers, but the synergistic anti-cancer effect of VPA and doxorubicin (DOX) combination treatment and its potential underlying mechanism in hepatocellular carcinoma (HCC) remain to be elucidated." | 3.85 | Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells. ( Cho, SG; Choi, HY; Dayem, AA; Kim, K; Saha, SK; Yang, GM; Yin, Y, 2017) |
| " Here, we compared combined effect of valproic acid (VPA), a class I and II HDAC inhibitor and antiepileptic drug with proton and photon irradiation in hepatocellular carcinoma (HCC) cells in vitro and in vivo." | 3.85 | Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation. ( Choi, C; Kim, SY; Lee, GH; Park, HC; Shin, SW; Son, A; Yu, JI, 2017) |
| "Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases." | 3.80 | Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. ( Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S, 2014) |
| " He had been obese, had been receiving a standard dose of valproic acid since clipping surgery for subarachnoid hemorrhage 17 years previously, and had not consumed any alcohol since the surgery." | 3.73 | Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. ( Iizuka, H; Katsuda, S; Okamoto, K; Sato, K; Ueda, Y; Ueno, K, 2005) |
| "For this purpose, PLC/PRF5 liver cancer cells were cultured, and after the overlapping of the cells reached about 80%, the cells were collected with trypsin and after washing, they were cultured on a plate with a concentration of 3 x 105." | 1.72 | Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line. ( Jiang, L; Liu, Y; Lu, Y; Zhang, K, 2022) |
| "Hepatocellular carcinoma (HCC), Primary liver cancer, is the fifth most common cancer in men." | 1.62 | Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Ce ( Kavoosi, F; Sanaei, M, 2021) |
| "However, its function in hepatocellular carcinoma (HCC) is not well-explored." | 1.48 | CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells. ( Cao, P; Chang, Y; Yang, L, 2018) |
| " The maximal in vivo VPA dosage that showed no significant cytotoxicity compared with control was 10 mg/kg/day." | 1.46 | Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. ( Chang, Y; Cho, E; Cho, H; Cho, YY; Kang, SH; Kim, YJ; Lee, DH; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2017) |
| "The human hepatoma cell line HepaRG has been used for human relevant toxicity assessment." | 1.40 | Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study. ( Klein, S; Mueller, D; Noor, F; Schevchenko, V, 2014) |
| "Valproic acid (VPA) is a potent anticancer and antiangiogenic agent." | 1.40 | Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties. ( Baabbad, A; El-Faham, A; Elkayal, AM; Farooq, M; Hamed, EA; Ibrahim, MF; Khattab, SN; Taha, NA; Wadaan, MA, 2014) |
| "We describe arginase deficiency in a 20-year-old woman with spastic paraplegia, progressive dystonia, dementia, peripheral neuropathy, epilepsy, liver cirrhosis, and non-B/non-C hepatocellular carcinoma." | 1.38 | Arginase deficiency with new phenotype and a novel mutation: contemporary summary. ( Ching, CK; Fung, CW; Lam, CW; Luk, HM; Mak, CM; Poon, WL; Siu, TS; Tam, S; Tsang, JP; Wong, VC, 2012) |
| "We examined the effect of VPA in human hepatocellular cancer cells (HuH7) in vitro and in vivo." | 1.37 | Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. ( Bellodi-Privato, M; D'Albuquerque, LA; de Oliveira, ER; Kubrusly, MS; Machado, MC; Molan, NA; Tharcisio, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Y | 1 |
| Liu, Y | 1 |
| Zhang, K | 1 |
| Jiang, L | 1 |
| Rithanya, P | 1 |
| Ezhilarasan, D | 1 |
| Grünig, D | 1 |
| Szabo, L | 1 |
| Marbet, M | 1 |
| Krähenbühl, S | 1 |
| Liu, J | 2 |
| Yang, X | 2 |
| Liang, Q | 2 |
| Yu, Y | 2 |
| Shen, X | 1 |
| Sun, G | 3 |
| Sanaei, M | 3 |
| Kavoosi, F | 3 |
| Saha, SK | 1 |
| Yin, Y | 1 |
| Kim, K | 1 |
| Yang, GM | 1 |
| Dayem, AA | 1 |
| Choi, HY | 1 |
| Cho, SG | 1 |
| Aucamp, J | 1 |
| Van Dyk, HC | 1 |
| Bronkhorst, AJ | 1 |
| Pretorius, PJ | 1 |
| Yu, JI | 1 |
| Choi, C | 1 |
| Shin, SW | 1 |
| Son, A | 1 |
| Lee, GH | 1 |
| Kim, SY | 1 |
| Park, HC | 1 |
| Berndt, N | 1 |
| Bulik, S | 1 |
| Wallach, I | 1 |
| Wünsch, T | 1 |
| König, M | 1 |
| Stockmann, M | 1 |
| Meierhofer, D | 1 |
| Holzhütter, HG | 1 |
| Yang, L | 1 |
| Chang, Y | 2 |
| Cao, P | 1 |
| Roustazadeh, A | 1 |
| Shahsavani, H | 1 |
| Li, X | 1 |
| Zhu, Y | 1 |
| He, H | 1 |
| Lou, L | 1 |
| Ye, W | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Klein, S | 1 |
| Mueller, D | 1 |
| Schevchenko, V | 1 |
| Noor, F | 1 |
| An, HM | 1 |
| Xue, YF | 1 |
| Shen, YL | 1 |
| Du, Q | 1 |
| Hu, B | 1 |
| Matsuda, Y | 1 |
| Wakai, T | 1 |
| Kubota, M | 1 |
| Osawa, M | 1 |
| Hirose, Y | 1 |
| Sakata, J | 1 |
| Kobayashi, T | 1 |
| Fujimaki, S | 1 |
| Takamura, M | 1 |
| Yamagiwa, S | 1 |
| Aoyagi, Y | 1 |
| Farooq, M | 1 |
| El-Faham, A | 1 |
| Khattab, SN | 1 |
| Elkayal, AM | 1 |
| Ibrahim, MF | 1 |
| Taha, NA | 1 |
| Baabbad, A | 1 |
| Wadaan, MA | 1 |
| Hamed, EA | 1 |
| Sun, L | 1 |
| Coy, DH | 1 |
| Wu, L | 1 |
| Feng, H | 1 |
| Hu, J | 1 |
| Tian, X | 1 |
| Zhang, C | 1 |
| Lee, DH | 1 |
| Nam, JY | 1 |
| Cho, H | 1 |
| Kang, SH | 1 |
| Cho, YY | 1 |
| Cho, E | 1 |
| Lee, JH | 1 |
| Yu, SJ | 1 |
| Kim, YJ | 1 |
| Yoon, JH | 1 |
| Tatebe, H | 1 |
| Shimizu, M | 1 |
| Shirakami, Y | 1 |
| Sakai, H | 1 |
| Yasuda, Y | 1 |
| Tsurumi, H | 1 |
| Moriwaki, H | 1 |
| Machado, MC | 1 |
| Bellodi-Privato, M | 1 |
| Kubrusly, MS | 1 |
| Molan, NA | 1 |
| Tharcisio, T | 1 |
| de Oliveira, ER | 1 |
| D'Albuquerque, LA | 1 |
| Tsang, JP | 1 |
| Poon, WL | 1 |
| Luk, HM | 1 |
| Fung, CW | 1 |
| Ching, CK | 1 |
| Mak, CM | 1 |
| Lam, CW | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Wong, VC | 1 |
| Singh, T | 1 |
| Prasad, R | 1 |
| Katiyar, SK | 1 |
| Kim, AJ | 1 |
| Shi, Y | 1 |
| Austin, RC | 1 |
| Werstuck, GH | 1 |
| Armeanu, S | 3 |
| Pathil, A | 3 |
| Venturelli, S | 3 |
| Mascagni, P | 2 |
| Weiss, TS | 2 |
| Göttlicher, M | 1 |
| Gregor, M | 2 |
| Lauer, UM | 3 |
| Bitzer, M | 3 |
| Krusch, M | 1 |
| Kaiser, S | 1 |
| Jobst, J | 1 |
| Smirnow, I | 1 |
| Wagner, A | 1 |
| Steinle, A | 1 |
| Salih, HR | 1 |
| Sato, K | 1 |
| Ueda, Y | 1 |
| Ueno, K | 1 |
| Okamoto, K | 1 |
| Iizuka, H | 1 |
| Katsuda, S | 1 |
| Schuchmann, M | 1 |
| Schulze-Bergkamen, H | 1 |
| Fleischer, B | 1 |
| Schattenberg, JM | 1 |
| Siebler, J | 1 |
| Weinmann, A | 1 |
| Teufel, A | 1 |
| Wörns, M | 1 |
| Fischer, T | 1 |
| Strand, S | 1 |
| Lohse, AW | 1 |
| Galle, PR | 1 |
| Seki, A | 1 |
| Inoue, T | 1 |
| Maegaki, Y | 1 |
| Sugiura, C | 1 |
| Toyoshima, M | 1 |
| Akaboshi, S | 1 |
| Ohno, K | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Michaud, L | 1 |
| Gottrand, F | 1 |
| Turck, D | 1 |
| Poher, M | 1 |
| Lecomte-Houcke, M | 1 |
| Farriaux, JP | 1 |
| Wood, BP | 1 |
1 review available for valproic acid and Cancer of Liver
| Article | Year |
|---|---|
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
33 other studies available for valproic acid and Cancer of Liver
| Article | Year |
|---|---|
Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Humans; Liver Neoplasms; Valp | 2022 |
Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Screenin | 2021 |
Valproic acid affects fatty acid and triglyceride metabolism in HepaRG cells exposed to fatty acids by different mechanisms.
Topics: Animals; Apolipoprotein B-100; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tu | 2020 |
Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Huma | 2020 |
Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug | 2021 |
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Ce
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme Inhi | 2021 |
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Caspase 3; Doxorubicin; Drug | 2017 |
Valproic acid alters the content and function of the cell-free DNA released by hepatocellular carcinoma (HepG2) cells in vitro.
Topics: Carcinoma, Hepatocellular; Cell Communication; DNA, Neoplasm; Glycolysis; Hep G2 Cells; Humans; Live | 2017 |
Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; Down-Regulation; Female | 2017 |
HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology.
Topics: Algorithms; Carcinoma, Hepatocellular; Enzyme Inhibitors; Galactosemias; Hepatocytes; Humans; Kineti | 2018 |
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Topics: Antigens, CD; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2018 |
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Topics: Acetylation; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Histone Deacetyla | 2018 |
Effect of DNA Methyltransferase in Comparison to and\
in Combination with Histone Deacetylase Inhibitors on\
Hepatocellular Carcinoma HepG2 Cell Line
Topics: Anticarcinogenic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; DNA Modification | 2019 |
Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aspirin; Blo | 2013 |
Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study.
Topics: Animal Testing Alternatives; Anticonvulsants; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Surv | 2014 |
Sodium valproate induces cell senescence in human hepatocarcinoma cells.
Topics: Acetylation; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tu | 2013 |
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, | 2014 |
Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Anticonvulsants; Carcinoma, Hepatoc | 2014 |
Valproic acid (VPA) promotes the epithelial mesenchymal transition of hepatocarcinoma cells via transcriptional and post-transcriptional up regulation of Snail.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelial-Mesenc | 2016 |
Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
Topics: Animals; Carcinoma, Hepatocellular; Cytokine-Induced Killer Cells; Disease Models, Animal; Drug Syne | 2017 |
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell L | 2009 |
Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dos | 2011 |
Arginase deficiency with new phenotype and a novel mutation: contemporary summary.
Topics: Anticonvulsants; Arginase; Base Sequence; Carcinoma, Hepatocellular; Cerebral Palsy; Codon, Nonsense | 2012 |
Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Topics: Acetylation; Animals; Biphenyl Compounds; Bronchi; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell | 2013 |
Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; | 2005 |
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cells, Cultured; Enzyme Inhib | 2005 |
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Topics: Carcinoma, Hepatocellular; Enzyme Inhibitors; Histocompatibility Antigens Class I; Histone Deacetyla | 2005 |
Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid.
Topics: Anticonvulsants; Carcinoma, Hepatocellular; Fatty Liver; Hepatitis; Humans; Liver Neoplasms; Male; M | 2005 |
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, | 2006 |
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; CASP8 an | 2006 |
[Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman].
Topics: Adenoma, Liver Cell; Adult; Epilepsy; Female; Humans; Hyperandrogenism; Liver Neoplasms; Polycystic | 2006 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Radiological case of the month. In utero ultrasonographic demonstration of a lymphangioma.
Topics: Adult; Epilepsy; Female; Fetal Diseases; Humans; Infant, Newborn; Liver Neoplasms; Lymphangioma, Cys | 1996 |